Toll样受体2基因I/D多态性与肿瘤相关性的Meta分析

Association between Toll like receptor 2 Gene I/D Polymorphism and Cancer Risk: A Meta-analysis

目的系统评价Toll样受体2(Toll like receptor 2,TLR2)基因I/D多态性与肿瘤发病风险的相关性。方法计算机检索Pub Med、EMbase、The Cochrane Library(2015年第7期)、CBM、CNKI、VIP和Wan Fang Data数据库,搜集关于TLR2基因I/D多态性与肿瘤发病风险相关性的病例-对照研究,检索时限均为建库至2015年7月。由2位评价员独立筛选文献、提取资料和评价纳入研究的偏倚风险后,采用Rev Man 5.2软件进行Meta分析。结果最终纳入13个病例-对照研究,共包括3 250例肿瘤患者和4 332例对照人群。Meta分析结果显示,TLR2基因I/D多态性与肿瘤发病风险相关[DD+DI vs.II:OR=1.60,95%CI(1.13,2.27),P=0.009;DD vs.II+DI:OR=1.73,95%CI(1.13,2.66),P=0.01;DD vs.II:OR=1.99,95%CI(1.22,3.24),P=0.006;DI vs.II:OR=1.52,95%CI(1.09,2.11),P=0.01;D vs.I:OR=1.54,95%CI(1.14,2.09),P=0.005]。结论 TLR2基因I/D多态性与肿瘤发病风险相关。受纳入研究数量及质量的限制,该结论需进一步进行验证。

Objective To systematically evaluate the association between Toll like receptor 2 （TLR2） gene I/D polymorphism and the risk of cancer. Methods We searched PubMed, EMbase, The Cochrane Library （Issue 7, 2015）, CBM, CNKI, VIP and WanFang Data to collect case-control studies about the association between TLR2 gene I/D polymorphism and the risk of cancer from inception to July 2015. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was conducted using RevMan 5.3 software. Results A total of 11 case- control studies involving 3 250 cancer patients and 4 332 controls were included. The results of meta-analysis showed that significant association was found between TLR2 gene I/D polymorphism and the risk of cancer （DD＋DI vs. II： OR=1.60, 95%CI 1.13 to 2.27, P=0.009; DD vs. II＋DI： OR=1.73, 95%CI 1.13 to 2.66, P=0.01; DD vs. II： OR=1.99, 95%CI 1.22 to 3.24, P=0.006; DI vs. II： OR=1.52, 95%CI 1.09 to 2.11, P=0.01; D vs. I： OR=1.54, 95%CI 1.14 to 2.09, P=0.005）. Conclusion TLR2 gene L/D polymorphism may be associated with cancer risk. Due to the limited quantity and quality of included studies, the conclusion should be verified in further studies.